Organizing Committee
OCM Member
President of Bawa Biotech LLC
Bawa Biotech LLC , USA
Biography :

Raj Bawa is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm based in Ashburn, VA, USA that he founded in 2002. He is an inventor, entrepreneur, professor and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for over two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery and biodefense, FDA regulatory issues, and patent law. Since 1999, he has held various positions at Rensselaer Polytechnic Institute in Troy, NY, where he is currently an adjunct professor of biological sciences and where he received his doctoral degree in three years (biophysics/biochemistry). Since 2004, he has been an adjunct professor of natural and applied sciences at NVCC in Annandale, VA. He is a scientific advisor to Teva Pharmaceutical Industries, Ltd., Israel. He has served as a principal investigator of National Cancer Institute SBIRs and reviewer for both the NIH and NSF. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner for 6 years. He is a life member of Sigma Xi, co-chair of the Nanotech Committee of the American Bar Association and serves on the global advisory council of the World Future Society. He is frequently interviewed by the media and appeared in such publications as Nature, MIT Technology Review, American Chemical Socitye CE&N, Business Review, etc. He has authored over 100 publications, co-edited four texts and serves on the editorial boards of 17 peer-reviewed journals, including serving as a Special Associate Editor of Nanomedicine (Elsevier) and an Editor-in-Chief of the Journal of Interdisciplinary Nanomedicine (Wiley). Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the Undersecretary of Commerce, Washington, DC (2001); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).

OCM Member
President
Foundation de Beaumont Bonelli for cancer research , Italy
Biography :

Giulio Tarro graduated from Medicine School, Naples University (1962), Italy. Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus (2006). Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). President, Foundation de Beaumont Bonelli for Cancer Research. His basic researches have been concerned with antigens induced early during the replication cycle of human herpesviruses. Another study has involved the identification, isolation and characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

OCM Member
Founder and Chairman Emeritus, Immunology
Vaccinogen Inc , USA
Biography :

Dr. Hanna is a co-founder of Vaccinogen, Inc., the discoverer and developer of OncoVAX, Vaccinogen’s lead project, and a pioneer in the field of cancer vaccines. He also developed and obtained FDA approval for TICE BCG for treatment of carcinoma in situ ("CIS") bladder cancer which remains the standard of care for prophylaxis of recurrence of superficial bladder cancer and therapy of CIS. Dr. Hanna has not only proven his capabilities as discoverer and developer of clinically beneficial biotherapeutics, but also has raised over $300 million for the final clinical development of OncoVAX. As the director of the National Cancer Institutes, Frederick Cancer Research Center, between 1975 – 1983, he created a center of research excellence and managed over 2,000 technologists consisting of hundreds of MDs and PhDs. A special committee of the National Cancer Advisory Board selected him for the above responsibilities. He previously served as Chairman (Emeritus) and Chief Scientific Officer of Intracel Resources, an integrated biopharmaceutical company that developed cancer vaccines and immunotherapeutic and diagnostic products for both cancers and infectious diseases. Dr. Hanna also served as President and Chief Executive Officer of PerImmune, Inc. before it and Intracel Corp. merged in 1998. From 1985 to 1994, he was the Chief Operating Officer of Organon Teknika Biotechnology Research Institute and Senior Vice President of Organon Teknika Corporation, a subsidiary of Akzo Nobel, N.V., The Netherlands. Prior to that, he was Director of the National Cancer Institute, Frederick Cancer Research Center. Dr. Hanna received a doctoral degree in experimental pathology and immunology from the University of Tennessee. He has over 225 publications to his credit, has 10 patents in immunotherapy and has been the recipient of numerous honors.

OCM Member
Founder Director Swasthya Santulan Medicare Pvt.Ltd
Swasthya Santulan Medicare Pvt. Ltd. , India
Biography :

? 1996 - Present (Total 21+ years) ? Founder Director Swasthya Santulan Medicare Pvt.Ltd. ? Working as Consulting Acupuncturist ? 2000- Present ? Founder, Director, Head of Management and Teacher, School of Alternative Healing and Acupuncture Insync ( Saheacci), Pune ? 2013-Present ? Authorized Teacher in Acupuncture for Beijing Mebo Training Centre, China for 8 advanced courses in Pulse Diagnosis ? 2016 - Present ? Authorized trainer for NADA ? 2017 ? Lecturer in Acupuncture at University of Perugia, Italy. ? 2017 ? Official Trainer

OCM Member
Immunology
National Research Center , Egypt
Biography :

Ahmed Hegazi is currently a Professor of Microbiology and Immunology in the National Research Center, Egypt. Prof. Hegazi received his master’s degree in 1979, and his PhD in 1981. Hegazi's research work has been focused lately on bee products and their therapeutic effects. Hegazi organized and contributed to national and international research projects since 1977 and up till now; he has been the principal investigator on multiple research projects within the National Research Center. He has published 211 scientific papers and articles in national and international journals. He also served on the board of multiple national and international scientific journals. Dr. Hegazi is also the president of the Egyptian Environmental Society for Uses and Production of Bee Products, secretary of the Egyptian Society of Apitherapy, secretary general of the African Federation of Apiculture Associations, and a member of the International Apitherapy Commission (APIMONDIA). Dr. Hegazi awards; First Class Decoration of Excellence, Egypt, 1995, The Senior Scientist Prize of National Research Center, Cairo, Egypt, 1996, The National Scientific Prize In Biological Sciences, Egypt, 1990, The Scientific Prize of The National Research Center, Cairo, Egypt, 1989, The Second Best Research Paper Award, International Congress of Propolis, Bones Aires, Argentina, 2000, Main Speaker Award,10th Academic Conference, PRA and NAS (Nippon Apitherapy Soc.) Japan, 2006, 2 Bronze medals from The International Innovation Fair of the Middle East, Kuwait, 2007 Awarded of Ghazi Wad Allah Salon Prize, 2008, Finally awarded the Merit Ward in Medical Sciences, National Research Centre, Egypt, 2016 and have 4 patents. a

Research Interest :

Immunology and Immunotherapy.

OCM Member
Immunology
Federal University of Rio de Janeiro , Brazil , Brazil
Biography :

Graduated in Biological Science (1990), Master in Parasitary Biology by Instituto Oswaldo Cruz-FIOCRUZ (1995), PhD in Sciences by the Institute of Microbiology Prof. Paulo de Góes of the Federal University of Rio de Janeiro (2000), Post-doctorate at the Laboratory of Immunopharmacology of the Department of Physiology and Pharmacodynamics of the Oswaldo Cruz Institute (2000-2002) and in the Program of Cell Biology of the National Jewish Medical and Research Center of Denver, Colorado, USA (2002-2004). He is currently Associate Professor I of the Immunobiology Program of the Biophysics Institute Carlos Chagas Filho of the Federal University of Rio de Janeiro. He has experience in Immunology, with emphasis on Cellular Immunology, Immunoparasitology and Immunomodulation, working mainly in the following subjects: Chagas disease, leishmaniasis, cryptococcosis,

Research Interest :

Experiente in Immunology, with enphasis in Cellular Immunology, Immunomodulation, Immunoparasitology and acting in following topics: Chagas diseases, Leishmaniasis, Cryptococcosis, Apoptosis and Inflammation

OCM Member
Dean (Students Affairs), Professor of Medical Microbiology, Immunology and Parasitology, Immunology and Parasitology
Avalon University School of Medicine , Netherlands
Biography :

M V Raghavendra Rao, PhD, worked as Professor of microbiology, parasitology, immunology and Epidemiology in many universities in India, China, Nepal, Libya, and Philippines. Currently, he is working at Avalon University School of Medicine, Curacao, Netherland Antilles. He has more than 40 years of teaching and research experience. He supervised 3 students for PhD, and 8 students for MPhil. He authored 18 text books. Three universities appointed him as their advisor and 3 universities acknowledged him with fellowships.

Research Interest :

Experiente in Immunology, with enphasis in Cellular Immunology, Immunomodulation, Immunoparasitology and acting in following topics: Chagas diseases, Leishmaniasis, Cryptococcosis, Apoptosis and Inflammation

OCM Member
Head of Scientific Research Board , Internal medicine-rheumatologist
University Medical Center, Belgrade , Serbia
Biography :

Ljudmila Stojanovich received her Ph.D. in Medicine, with the thesis “Neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus” in 1999. She is the scientific director in the Bezhanijska Kosa, University Medical Center of Belgrade University, where she is currently a Full Research Professor. Dr. Stojanovich’s research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings.  She is in Editorial Boards (Editorial Boards LUPUS (LONDON). /Reviewer in the “CURRENT CONTENSTS” or “Science citation index”, like LUPUS REWIEWER DATABAS, Cellular and Molecular Neurobiology, The Journal of  Vaccine <jvac@elsevier.com , The Journal of Rheumatology, Allergologia et Immunopathologia and others. She is a member of number International Project, like of “the European Forum on Antiphospholipid Antibodies”, “Multicenter studies antiphospholipid antibodies, infections and autoimmune diseases”. She is a mentor/ Supervisor ships a numbers of post-doc students.  She was in Invited Speaker for many lectures in Congresses and Symposia; organizer and Chairman of many Workshops, Seminars and Symposia; the member of the Steering Committee of the “(EULAR) recommendations for vaccination in patients with auto-immune inflammatory rheumatic diseases (AIIRD)”, and EULAR Honorary Member; chairman in the International Congress “Antiphospholipid syndrome (Hughes syndrome) importance of multidisciplinary approaches- 30 years since definition”, 2013, “GRANT 2015” of the EUROPEAN STROKE CONFERENCE » for “excellent research in cerebrovascular diseases reviewed by the Scientific and programmer Committees”, and presented at the 24th Annual Meeting; Vienna, may, 2015. Member of ILLUMINATE steering committee: the phase 3 lupus ILLUMINATES clinical trials of Tabalumab/ Eli Lilly and Company, MD, PhD, FRCP, are willing to serve as a consultant to Lilly Research Laboratories, a division of Eli Lilly and Company (“Lilly”), in connection with the development of Tabalumab also known as LY2439821. Co- Chairman and the lector “LUPUS ACADEMY EASTERN EUROPEAN ROADSHOW of  EULAR«: Belgrade, 18TH march 2016, www.lupus-academy.org.  Member of the American Association for the Advancement of Science (AAAS) from 2017; The Member  of the international team of medical experts for the topic on APS (Hughes Sy). Professor Ljudmila Stojanovich’ Impact Point is 300.14, and number of citattions is 1,998.  

Research Interest :

Experiente in Immunology, with enphasis in Cellular Immunology, Immunomodulation, Immunoparasitology and acting in following topics: Chagas diseases, Leishmaniasis, Cryptococcosis, Apoptosis and Inflammation

OCM Member
Head of the Department, Immunology
Russian Academy of Sciences, Saratov , Russia
Biography :

Sergey Suchkov was born in the City of Astrakhan, Russia, in a family of dynasty medical doctors. In 1980, graduated from Astrakhan State Medical University and was awarded with MD. In 1985, maintained his PhD as a PhD student of the I.M. Sechenov Moscow Medical Academy and Institute of Medical Enzymology, USSR Academy of Medical Sciences, Moscow, Russia. In 2001, finished the PostDoc Research Fellowship Program and maintained his Doctor Degree at the National Institute of Immunology, Russia. From 1985 through 1987, worked at Inst of Med Enzymology, USSR Academy of Medical Sciences. From 1987 through 1989, was a senior Researcher, Koltzov Inst of Developmental Biology, USSR Academy of Sciences. From 1989 through 1995, was being a Head of the Lab of Clinical Immunology and Immunobiotechnology, Helmholtz Eye Research Inst in Moscow. From 1995 through 2004, was being a Chairman of the Dept for Clinical Immunology, Moscow Clinical Research Institute (MONIKI) and the Immunologist-in-Chief of the Moscow Regional Ministry of Health.In 1993-1996, was an Executice Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Dr Suchkov is a Co-Supervisor over the Russian-American Agreement on scientific and clinical collaboration in the field of ocular immunology between Russian Academy of Sciences and National Institutes of Health (NIH); in 1991-1995 – a member of The Reciprocal Exchange Fellowship Program between Russian Immunological Society and British Society for Immunology. Dr Suchkov is a member of the Editorial Boards of many international journals including EPMA Journal (Springer, Brussels) and “Personalized Medicine Universe” (Elsevier, Japan).

Research Interest :

Experiente in Immunology, with enphasis in Cellular Immunology, Immunomodulation, Immunoparasitology and acting in following topics: Chagas diseases, Leishmaniasis, Cryptococcosis, Apoptosis and Inflammation

OCM Member
Ben Gurion University of Negev , Israel
Biography :

Noah Isakov is a Professor of Immunology in the Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, at Ben Gurion University of the Negev, in Beer Sheva, Israel, where he holds the Joseph H Krupp Chair in Cancer Immunobiology. He obtained his PhD from the Weizmann Institute of Science in Rehovot, Israel (1981) and worked as a postdoctoral researcher at the University of Minnesota in Minneapolis, MN (1981-1983) and the Scripps Research Institute in La Jolla, CA (1983-1987). He performed sabbaticals at the NICHD, National Institutes of Health in Bethesda, MD (1993-1995), the Oklahoma Medical Research Foundation in Oklahoma City, OK (2003-2004), where he held the Esther Greenberg Honors Chair in Biomedical Research, and the Otago University in Dunedin, New Zealand (2015).

Research Interest :

Research Specialist from the Oswaldo Cruz Foundation-FIOCRUZ

OCM Member
Head of Immunology/ Serology/ HLA section at Pathology and Clinical Laboratory
King Fahad Medical City , Saudi Arabia
Biography :

Aziz Alami Chentoufi is a Consultant and Head of Immunology/Serology/HLA section at Pathology and Clinical Laboratory Medicine, King Fahad Medical City (KFMC). He is also an Assistant Professor of Immunology at Faculty of Medicine, King Saud Ibn AbdulAziz University. He is the Chairperson of Research Committee of PCLMA-KFMC. He is the Diplomate of the American Board of Medical laboratory Immunology D(ABMLI ), Fellow of the Association of Clinical Sciences (FACSc), accredited by the European Society of Translational Medicine (PCTM) and Fellow of the Academy of translational Medicine (FacadTM). He received his Ph.D. in Biomedical Sciences (Tolerance induction to xenogenic and allogenic antigens using monoclonal antibody anti-igM and anti-IgD) from the University Catholic of Louvain, Brussels, Belgium in 1999. He has done postdoctoral fellowship at McGill University, Montreal, Canada from 1999 to 2004 where he worked on immunogenetic of type 1 Diabetes and gene therapy for graft versus host disease then he was appointed as specialist at the University of California Irvine-Medical Center, Irvine, California, USA in 2006 where he was a key investigator in the development of mucosal vaccine against herpes simplex virus type 1 and 2.

Research Interest :

Research Specialist from the Oswaldo Cruz Foundation-FIOCRUZ

OCM Member
Shraga Segal Department of Microbiology, Immunology and Genetics
Ben Gurion University of Negev , Israel
Biography :

Yaffa Mizrachi Nebenzahl has completed her PhD at The Weizmann Institute, Israel in 1985. She is the Head of the Molecular Microbiology Laboratory in The Shraga Segal Department of Microbiology, Immunology and Genetics at the Faculty of Health Sciences in Ben Gurion University of the Negev, Israel.

Research Interest :

Research Specialist from the Oswaldo Cruz Foundation-FIOCRUZ

Allied Academies Global Conference Directory

Mail us at

Congress Queries
immunology2k18@gmail.com
For Hotel Bookings
immunologycongress@alliedconference.com
Sponsors
sponsoraac@alliedacademies.com
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

Responsibility

Delegates are personally responsible for their belongings at the venue. The Organizers will not be held responsible for any stolen or missing items belonging to Delegates, Speakers or Attendees; due to any reason whatsoever.

Insurance

Registration fees do not include insurance of any kind.

Transportation

Please note that any (or) all transportation and parking is the responsibility of the registrant.

Press/Media

Press permission must be obtained from Allied academies Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied academies are a non-profit organization. This conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference. Once your registration is complete, please contact immunologycongress@alliedconferences.org to request a personalized letter of invitation.

 

Regarding refunds, all bank charges will be for the registrants account.

 

Cancellation, Postponement and Transfer of Registration

All cancellations or modifications of registration must be made in writing to Program Manager.

Cancellation Policy

If Allied academies cancel this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied academies conferences event which must occur within one year from the date of cancellation.

Postponement

If Allied academies postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another Allied academies conferences event which must occur within one year from the date of postponement.

Transfer of registration

All fully paid registrations are transferable to other persons from the same organization, if registered person is unable to attend the event. Transfers must be made by the registered person in writing to Program Manager. Details must be included with the full name of replacement person, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if it is intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues cannot come under the consideration of cancellation policy of Allied academies, including the inability to obtain a visa.

Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overheads, we had to keep Refund Policy is as following slabs-

  • Before 60 days of the conference: Eligible for Full Refund less $100 service Fee
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Providers (Hotels) have their own cancellation policies, and they generally apply when cancellations are made less than 30 days prior to arrival. Please contact us as soon as possible, if you wish to cancel or amend your accommodation. Allied academies will advise the cancellation policy of your accommodation provider, prior to cancelling or amending your booking, to ensure you are fully aware of any non-refundable deposits.

 

 

Authorization Policy


Copyright © 2018-2019 Allied Academies, All Rights Reserved.